Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum
Open Access
- 15 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1346749
Abstract
Introduction: Several novel vaccine platforms aim at mucosal immunity in the respiratory tract to block SARS-CoV-2 transmission. Standardized methods for mucosal sample collection and quantification of mucosal antibodies are therefore urgently needed for harmonized comparisons and interpretations across mucosal vaccine trials and real-world data.Methods: Using commercial electrochemiluminescence antibody panels, we compared SARS-CoV-2 spike-specific IgA and IgG in paired saliva, nasal secretions, and serum from 1048 healthcare workers with and without prior infection.Results: Spike-specific IgA correlated well in nasal secretions and saliva (r>0.65, p<0.0001), but the levels were more than three-fold higher in nasal secretions as compared to in saliva (p<0.01). Correlations between the total population of spike-specific IgA and spike-specific secretory IgA (SIgA) were significantly stronger (p<0.0001) in nasal secretions (r=0.96, p<0.0001) as opposed to in saliva (r=0.77, p<0.0001), and spike-specific IgA correlated stronger (p<0.0001) between serum and saliva (r=0.73, p<0.001) as opposed to between serum and nasal secretions (r=0.54, p<0.001), suggesting transudation of monomeric spike specific IgA from the circulation to saliva. Notably, spike-specific SIgA had a markedly higher SARS-CoV-2 variant cross-binding capacity as compared to the total population of spike specific IgA and IgG in both nasal secretions, saliva and serum, (all p<0.0001), which emphasizes the importance of taking potential serum derived monomeric IgA into consideration when investigating mucosal immune responses.Discussion: Taken together, although spike-specific IgA can be reliably measured in both nasal secretions and saliva, our findings imply an advantage of higher levels and likely also a larger proportion of SIgA in nasal secretions as compared to in saliva. We further corroborate the superior variant cross-binding capacity of SIgA in mucosal secretions, highlighting the potential protective benefits of a vaccine targeting the upper respiratory tract.Keywords
This publication has 41 references indexed in Scilit:
- Mucosal vaccines for SARS-CoV-2: triumph of hope over experienceEBioMedicine, 2023
- SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccinationEBioMedicine, 2022
- Mucosal plasma cells are required to protect the upper airway and brain from infectionImmunity, 2022
- Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in SwedenThe Lancet Regional Health - Europe, 2022
- Intranasal COVID-19 vaccines: From bench to bedEBioMedicine, 2022
- Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over timeClinical & Translational Immunology, 2022
- Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2EBioMedicine, 2021
- Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care WorkersJAMA, 2021
- Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell OriginsCell Reports, 2017
- Immunoglobulins and complement in crevicular fluid, serum and saliva in manArchives of Oral Biology, 1972